Literature DB >> 33788803

The Use of Tranexamic Acid in Hip and Pelvic Fracture Surgeries.

John D Adams1, William A Marshall.   

Abstract

Tranexamic acid (TXA) use has expanded across many surgical specialties. It has been shown to reduce blood loss, decrease transfusion rates, and, in some cases, improve mortality. Within orthopaedic surgery, its popularity has primarily grown within arthroplasty and spinal surgery. It has only recently gained traction within the field of orthopaedic trauma and fracture care. At this time, most literature focuses on hip fracture and pelvic trauma surgery. For hip fractures, the results are encouraging and generally support the claim that TXA may lower overall blood loss and decrease transfusions. Conversely, less support exists for TXA use in fractures of the acetabulum or pelvic ring. Based on the current fracture-related studies, TXA does not seem to carry an increased risk of thromboembolism or other complications. In addition, few studies have been noted discussing the route of administration, timing, or dosage. This article reviews the most current literature regarding TXA use in fracture care and expands on the need for further research to evaluate the role of TXA in orthopaedic trauma populations who carry a high risk for transfusion.
Copyright © 2021 by the American Academy of Orthopaedic Surgeons.

Entities:  

Year:  2021        PMID: 33788803     DOI: 10.5435/JAAOS-D-20-00750

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  2 in total

1.  Is intravenous tranexamic acid effective in reduction of blood loss during pelvic and acetabular surgery?

Authors:  Mohamed M F Sharaby; Younes M El-Deeb
Journal:  Int Orthop       Date:  2022-05-07       Impact factor: 3.479

2.  Intravenous Tranexamic Acid Decreases Blood Transfusions and Blood Loss for Patients with Surgically Treated Hip Fractures.

Authors:  Phuong Anh N Huynh; Megan Miller; Ryan Will
Journal:  Geriatr Orthop Surg Rehabil       Date:  2021-12-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.